Literature DB >> 16863430

Functional interactions between P-glycoprotein and CYP3A in drug metabolism.

Uwe Christians1, Volker Schmitz, Manuel Haschke.   

Abstract

The interaction between drug-metabolising enzymes and active transporters is an emerging concept in pharmacokinetics. In the gut mucosa, P-glycoprotein and cytochrome P450 (CYP)3A functionally interact in three ways: i) drugs are repeatedly taken up and pumped out of the enterocytes by P-glycoprotein, thus increasing the probability of drugs being metabolised; ii) P-glycoprotein keeps intracellular drug concentrations within the linear range of the metabolising capacity of CYP3A; and iii) P-glycoprotein transports drug metabolites formed in the mucosa back into the gut lumen. In comparison with the gut mucosa, in hepatocytes the spatial sequence of CYP3A and P-glycoprotein is reversed, resulting in different effects when the activity of one or both are changed. CYP3A and P-glycoprotein are both regulated by nuclear receptors such as the pregnane X receptor (PXR). There is significant genetic variability of CYP3A, P-glycoprotein and PXR and their expression and activity is dependent on coadministered drugs, herbs, food, age, hormonal status and disease. Future pharmacogenomic and pharmacokinetic studies will have to take all three components into account to allow for valid conclusions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16863430     DOI: 10.1517/17425255.1.4.641

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  28 in total

Review 1.  Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.

Authors:  Enoche F Oga; Shuichi Sekine; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-04       Impact factor: 2.441

Review 2.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 3.  Pharmacogenomics of CYP3A: considerations for HIV treatment.

Authors:  Sukhwinder S Lakhman; Qing Ma; Gene D Morse
Journal:  Pharmacogenomics       Date:  2009-08       Impact factor: 2.533

Review 4.  [Drug interactions in geriatric medicine].

Authors:  Angela Storka; Johannes Pleiner
Journal:  Wien Med Wochenschr       Date:  2009

Review 5.  Interplay of drug metabolizing enzymes with cellular transporters.

Authors:  Michaela Böhmdorfer; Alexandra Maier-Salamon; Juliane Riha; Stefan Brenner; Martina Höferl; Walter Jäger
Journal:  Wien Med Wochenschr       Date:  2014-09-10

6.  Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism.

Authors:  Shripad D Chitnis; Ken Ogasawara; Björn Schniedewind; Reginald Y Gohh; Uwe Christians; Fatemeh Akhlaghi
Journal:  Xenobiotica       Date:  2013-01-02       Impact factor: 1.908

7.  Should we stop dosing steroids per body surface area for nephrotics?

Authors:  Guido Filler; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2015-12-28       Impact factor: 3.714

Review 8.  Everolimus and sirolimus in transplantation-related but different.

Authors:  Jost Klawitter; Björn Nashan; Uwe Christians
Journal:  Expert Opin Drug Saf       Date:  2015-04-26       Impact factor: 4.250

Review 9.  PXR: More Than Just a Master Xenobiotic Receptor.

Authors:  Peter O Oladimeji; Taosheng Chen
Journal:  Mol Pharmacol       Date:  2017-11-07       Impact factor: 4.436

10.  Using expression and genotype to predict drug response in yeast.

Authors:  Douglas M Ruderfer; David C Roberts; Stuart L Schreiber; Ethan O Perlstein; Leonid Kruglyak
Journal:  PLoS One       Date:  2009-09-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.